Spojené státy - angličtina - NLM (National Library of Medicine)

mayne pharma inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes, streptococcus pneumoniae, or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pneumoniae or streptococcus pyogenes. listeriosis caused by listeria monocytogenes. pertussis (whooping cough) caused by bordetella pertussis. erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible indivi

Spojené státy - angličtina - NLM (National Library of Medicine)

direct rx - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 5 mg in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. for prophylaxis of ophthalmia neonatorum due to n. gonorrhoeae or c. trachomatis. the effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing n. gonorrhoeae is not established. for infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin g should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. topical prophylaxis alone is inadequate for these infants. this drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

Spojené státy - angličtina - NLM (National Library of Medicine)

h.j. harkins company, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 5 mg in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. for prophylaxis of ophthalmia neonatorum due to n. gonorrhoeae or c. trachomatis . the effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing n. gonorrhoeae is not established. for infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin g should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. topical prophylaxis alone is inadequate for these infants. this drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

Spojené státy - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg - erythromycin pledgets, usp are indicated for the topical treatment of acne vulgaris. erythromycin pledgets, usp are contraindicated in those individuals who have shown hypersensitivity to any of its components.

Spojené státy - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - erythromycin 30 mg in 1 g - erythromycin-benzoyl peroxide topical gel is indicated for the topical treatment of acne vulgaris. erythromycin-benzoyl peroxide topical gel is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Spojené státy - angličtina - NLM (National Library of Medicine)

central texas community health centers - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 5 mg in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. for prophylaxis of ophthalmia neonatorum due to n. gonorrhoeae or c. trachomatis . the effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing n. gonorrhoeae is not established. for infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin g should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. topical prophylaxis alone is inadequate for these infants. this drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

Spojené státy - angličtina - NLM (National Library of Medicine)

sandoz inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 30 mg in 1 g - erythromycin and benzoyl peroxide topical gel usp, 3%;5% is indicated for the topical treatment of acne vulgaris. erythromycin and benzoyl peroxide topical gel usp, 3%;5% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Spojené státy - angličtina - NLM (National Library of Medicine)

bausch & lomb incorporated - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 5 mg in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. for prophylaxis of ophthalmia neonatorum due to n. gonorrhoeae or c. trachomatis . the effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing n. gonorrhoeae is not established. for infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin g should be given: a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. topical prophylaxis alone is inadequate for these infants. this drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

Spojené státy - angličtina - NLM (National Library of Medicine)

wilshire pharmaceuticals - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrati

Spojené státy - angličtina - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release tablets and other antibacterial drugs, erythromycin delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.   erythromycin delayed-release tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes or streptococcus pneumoniae . listeriosis caused by listeria monocytogenes . respiratory tract infections due to mycoplasma pneumoniae . skin and skin structure infections of mild to moderate severity caused by streptococcus pyogenes or staphylococcus aureus (resistant staphylococci may emerge during treatment). pertussis (whooping cough) caused by bordetella pertussis . erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. diphtheria: infections due to corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum . intestinal amebiasis caused by entamoeba histolytica (oral erythromycins only). extraenteric amebiasis requires treatment with other agents. acute pelvic inflammatory disease caused by neisseria gonorrhoeae : erythromycin lactobionate for injection, usp followed by erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. erythromycin delayed-release tablets are indicated for treatment of the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. when tetracyclines are contra-indicated or not tolerated, erythromycin delayed-release tablets are indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to chlamydia trachomatis . when tetracyclines are contraindicated or not tolerated, erythromycin delayed-release tablets are indicated for the treatment of nongonococcal urethritis caused by ureaplasma urealyticum . primary syphilis caused by treponema pallidum . erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. in treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the follow-up after therapy. legionnaires’ disease caused by legionella pneumophila . although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires’ disease. prophylaxis prevention of initial attacks of rheumatic fever penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of streptococcus pyogenes infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis)1 . erythromycin delayed-release tablets are indicated for the treatment of penicillin-allergic patients. the therapeutic dose should be administered for ten days. prevention of recurrent attacks of rheumatic fever penicillin or sulfonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the american heart association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever)1 . erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic. erythromycin is contraindicated in patients taking terfenadine, astemizole, cisapride, pimozide, ergotamine, or dihydroergotamine (see precautions - drug interactions ). do not use erythromycin concomitantly with hmg coa reductase inhibitors (statins) that are extensively metabolized by cyp 3a4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.